Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
liver save search
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
OABI | $4.59 -3.98% -3.91% 1.1M
|
|
| O: -1.58%
H: 1.77%
C: -0.4%
drug liver disease antibody for
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
CANF | $1.97 0.51% -3.05% 10K
|
Health Technology
|
| O: 4.76%
H: 0.45%
C: -5.91%
drug candidate liver cancer treat namodenoson advanced
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
ONVO | $1.15 2.68% 6.28% 580K
|
Health Technology
|
| O: 64.34%
H: 4.82%
C: -18.67%
fxr314 metabolic liver positive for results
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
MDGL | $222.26 -2.66% -2.8% 220K
|
Health Technology
|
| O: 2.12%
H: 0.7%
C: -0.82%
liver treatment fibrosis pharmaceuticals for advanced nash
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
Published: 2024-04-08 (Crawled : 17:00) - globenewswire.com
INKT | $0.8717 -4.76% 0.51% 43K
|
|
| O: 1.28%
H: 0.0%
C: -16.46%
nk-215 liver cancer preclinical therapeutics
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
Published: 2024-04-01 (Crawled : 12:30) - globenewswire.com
SRZN | $9.33 -0.32% 9.39% 29K
|
|
| O: -8.98%
H: 4.61%
C: -29.37%
szn-043 liver
Promising First-In-Human Phase 1B Clinical Study Data from VRON-0200, a Novel, First-in-Class Checkpoint Modifier Immunotherapy for Chronic Hepatitis B Virus Functional Cure, Presented as Late-Breaker at 2024 APASL Global Liver Meeting
Published: 2024-03-28 (Crawled : 00:00) - prnewswire.com
OCEA | $1.875 5.04% 4.55% 210K
|
|
| O: 0.49%
H: 0.0%
C: -7.23%
vron-0200 hepatitis liver global immunotherapy meeting virus study
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis
Published: 2024-03-15 (Crawled : 13:00) - prnewswire.com
GLMD | $0.3787 2.8% -0.41% 27K
|
Health Technology
|
| O: 17.48%
H: 0.0%
C: -25.59%
mgl-3196 patent liver treatment fibrosis grant aramchol nash
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
Published: 2024-03-14 (Crawled : 20:00) - globenewswire.com
MDGL | $222.26 -2.66% -2.8% 220K
|
Health Technology
|
| O: 20.66%
H: 2.07%
C: -8.01%
fda liver approval treatment fibrosis pharmaceuticals advanced
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
Published: 2024-03-11 (Crawled : 12:30) - biospace.com/
CANF | $1.97 0.51% -3.05% 10K
|
Health Technology
|
| O: -0.45%
H: 2.27%
C: 2.27%
europe liver conference distribution pancreatic treatment namodenoson
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
Published: 2024-03-06 (Crawled : 14:00) - globenewswire.com
INKT | $0.8717 -4.76% 0.51% 43K
|
|
| O: 1.02%
H: 0.48%
C: -1.41%
nk-215 liver cancer preclinical
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024MiNK-215 Eradicated Tumor Cells in Human Organoid MSS Colorectal Cancer Liver Metastases Model
Published: 2024-03-06 (Crawled : 14:00) - biospace.com/
INKT | $0.8717 -4.76% 0.51% 43K
|
|
| O: 1.02%
H: 0.48%
C: -1.41%
nk-215 liver cancer tumor preclinical
Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis
Published: 2024-03-05 (Crawled : 13:00) - globenewswire.com
MDGL | $222.26 -2.66% -2.8% 220K
|
Health Technology
|
| O: -0.86%
H: 2.04%
C: 1.66%
liver authorization treatment fibrosis pharmaceuticals ema application
Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver Meeting
Published: 2024-02-29 (Crawled : 13:00) - globenewswire.com
OCEA | $1.875 5.04% 4.55% 210K
|
|
| O: 2.6%
H: 36.71%
C: 11.39%
first liver presentation global meeting therapeutics study
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Published: 2024-02-26 (Crawled : 07:00) - globenewswire.com
ZEAL | $17.59 1.21% -4.21%
|
Health Technology
| Email alert
Add to watchlist
pharma liver disease fibrosis trial results
Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease
Published: 2024-02-20 (Crawled : 15:30) - biospace.com/
BTTX | $0.009 -3.23% -65.02% 0
|
|
| O: 7.55%
H: 2.13%
C: -27.83%
fda device liver disease designation therapeutics advanced platform
Nanox Receives FDA Clearance for HealthFLD, an Advanced AI-Based Software Empowering Clinicians in Assessment of Fatty Liver
Published: 2024-02-13 (Crawled : 13:00) - globenewswire.com
NNOX | $9.07 -3.0% -2.86% 620K
|
Health Technology
|
| O: -6.78%
H: 2.42%
C: -3.55%
fda liver software clearance advanced
Liver Disease Therapeutics Competitive Landscape and Market Forecasts to 2028
Published: 2024-02-12 (Crawled : 20:00) - prnewswire.com
ALPMY | $9.47 0.11% -1.11% 520K
|
Manufacturing
|
| O: 0.37%
H: 0.74%
C: 0.28%
BMY | $48.3 0.96% 0.33% 8.9M
|
Health Technology
|
| O: -0.18%
H: 0.48%
C: -1.91%
ABBV | News | $164.66 0.25% -0.14% 3.6M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
GILD | News | $66.16 -1.15% -1.16% 4.9M
|
Health Technology
|
| O: 0.32%
H: 0.11%
C: -1.55%
ALNY | News | $145.16 -0.11% -0.19% 400K
|
Health Technology
|
| O: -2.63%
H: 0.98%
C: -1.75%
liver disease therapeutics market
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
Published: 2024-02-12 (Crawled : 14:30) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 4.9M
|
Health Technology
|
| O: -0.35%
H: 2.36%
C: 1.42%
CBAY | $32.48 0.03% 8.4M
|
Health Technology
|
| O: 27.92%
H: 0.97%
C: 0.88%
liver acquisition sciences therapeutics
New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload
Published: 2024-02-06 (Crawled : 14:00) - globenewswire.com
NUWE | $0.2604 -6.26% -6.03% 520K
|
Manufacturing
|
| O: 6.25%
H: 0.78%
C: -12.75%
aquadex liver disease series potential therapy
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
ZCMD | $1.45 5.84% 49.63% 15M
|
Commercial Services
TPET | $0.3279 -3.56% 28.48% 33M
|
n/a
VTNR 4 | $1.31 33.78% 25.82% 220K
|
Industrial Services
GDHG | $0.263 21.76% 25.34% 1.3M
|
HOLO | $2.95 31.7% 22.49% 37M
|
MTNB | $0.19 -1.04% 14.58% 950K
|
Health Technology
UMAC | $1.55 0.65% 12.9% 0
|
TAOP | $1.08 13.01% 11.51% 19K
|
Technology Services
MGLD 4 | $1.13 5.61% 10.62% 200
|
Manufacturing
NURO | $3.65 2.24% 10.3% 3.9K
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.